Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
Top Cited Papers
- 25 May 2004
- journal article
- clinical trial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 101 (23) , 8705-8708
- https://doi.org/10.1073/pnas.0402653101
Abstract
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.Keywords
This publication has 16 references indexed in Scilit:
- Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials1Transplantation, 2004
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- Prospective study on the relationship between infections and multiple sclerosis exacerbationsBrain, 2002
- Daclizumab: outcome of phase III trials and mechanism of actionTransplantation Proceedings, 1998
- Correspondence of closest gradient Voxels—A robust registration algorithmJournal of Magnetic Resonance Imaging, 1997
- Clinical scales for multiple sclerosisJournal of the Neurological Sciences, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Method for Quantification of Brain, Ventricular, and Subarachnoid CSF Volumes from MR ImagesJournal of Computer Assisted Tomography, 1992
- Rating neurologic impairment in multiple sclerosisNeurology, 1983